{"nctId":"NCT03460990","briefTitle":"A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)","startDateStruct":{"date":"2018-05-01","type":"ACTUAL"},"conditions":["Cystic Fibrosis"],"count":116,"armGroups":[{"label":"TEZ/IVA","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: TEZ/IVA","Drug: IVA","Drug: Placebo"]},{"label":"VX-659/TEZ/IVA TC","type":"EXPERIMENTAL","interventionNames":["Drug: VX-659/TEZ/IVA","Drug: IVA","Drug: Placebo"]}],"interventions":[{"name":"VX-659/TEZ/IVA","otherNames":["VX-659/VX-661/VX-770","VX-659/tezacaftor/ivacaftor"]},{"name":"TEZ/IVA","otherNames":["VX-661/VX-770","tezacaftor/ivacaftor"]},{"name":"IVA","otherNames":["VX-770","ivacaftor"]},{"name":"Placebo","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Homozygous for the F508del mutation (F/F)\n* Forced expiratory volume in 1 second (FEV1) value ≥40% and ≤90% of predicted mean for age, sex, and height\n\nKey Exclusion Criteria:\n\n* Clinically significant cirrhosis with or without portal hypertension\n* Lung infection with organisms associated with a more rapid decline in pulmonary status\n* Solid organ or hematological transplantation\n\nOther protocol defined Inclusion/Exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)","description":"FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.9"},{"groupId":"OG001","value":"10.2","spread":"0.9"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Sweat Chloride (SwCl)","description":"Sweat samples were collected using an approved collection device.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"1.8"},{"groupId":"OG001","value":"-47.2","spread":"1.9"}]}]}]},{"type":"SECONDARY","title":"Absolute Change in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score","description":"The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms, score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.0","spread":"1.7"},{"groupId":"OG001","value":"16.5","spread":"1.7"}]}]}]},{"type":"SECONDARY","title":"Safety and Tolerability as Assessed Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Observed Pre-Dose Concentration (Ctrough) of VX-659, TEZ, TEZ Metabolite (M1-TEZ), and IVA","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[]},{"categories":[{"measurements":[{"groupId":"OG001","value":"720","spread":"589"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1780","spread":"832"},{"groupId":"OG001","value":"1590","spread":"1020"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1730","spread":"885"},{"groupId":"OG001","value":"1280","spread":"594"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5170","spread":"1620"},{"groupId":"OG001","value":"4840","spread":"1860"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5010","spread":"1810"},{"groupId":"OG001","value":"4730","spread":"1380"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"717","spread":"616"},{"groupId":"OG001","value":"563","spread":"400"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"722","spread":"642"},{"groupId":"OG001","value":"401","spread":"211"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":57},"commonTop":["Infective pulmonary exacerbation of cystic fibrosis","Sputum increased","Headache","Cough","Alanine aminotransferase increased"]}}}